The approvals were based on positive results from EV-302, in which Padcev plus Keytruda resulted in statistically significant ...

The cell and gene therapies in rare disorders market is expected to grow at a significantly high rate during the forecast period (2025–2034) and mainly be driven by an increase in approval of a ...

FibroGen (NASDAQ:FGEN – Get Free Report) and Roche (OTCMKTS:RHHBY – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the ...

A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...

Astellas has shored up the competitive profile of Izervay as a treatment for eye disorder geographic atrophy (GA), getting FDA approval for an extended treatment duration. The US regulator turned ...

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

What is a menopause health assessment? And how will it improve the health care women receive during this stage in their lives ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Researchers at Penn Medicine conducted a pilot randomized controlled trial to test the hypothesis that an e-triage ...

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...